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This document presents the official recommendations of the American 
Gastroenterological Association (AGA) regarding quality measures related to the 
diagnosis and management of the novel coronavirus, SARS-CoV-2. The current report 
outlines the process by which the Quality Committee (QC) evaluates guidance 
statements published by the AGA’s Clinical Guidelines Committee (CGC) to inform 
measure development. The recommendations discussed in this report relate to what 
remains an unprecedented event in contemporary history with unique challenges for 
CGC guidance-related measure development. The following recommendations were 
developed by the QC in consultation with the CGC. Their development was fully funded 
by the AGA Institute, with no additional outside funding.  
The novel coronavirus, SARS-CoV-2, was first described in December 2019 in patients 
in Wuhan, China who developed severe pneumonia, and was named coronavirus-19 
disease (COVID-19) by the World Health Organization on February 11, 20201. It was 
classified as a pandemic on March 11, 20202 and there have been 9,105,230 cases in 
the United States as of November 1, 20203. It is readily transmitted via aerosols4. Since 
the first descriptions of the pulmonary complications, numerous extra-intestinal 
manifestations have been described as well as gastrointestinal (GI) symptoms that 
include abdominal pain, nausea, vomiting, and diarrhea in addition to elevated 
transaminases. The target entry receptor for SARS-CoV-2 is thought to be ACE2 
(angiotensin converting enzyme II), which is expressed throughout the upper and lower 
gastrointestinal tract as well as hepatobiliary parenchyma. As a result, endoscopic GI 
procedures in particular are considered high-risk encounters. Although progress has 
been made in the treatment of COVID-19 infections, and early results appear promising 
regarding vaccine development, there remains no cure. Therefore, infection control and 
prevention remain paramount.  
 
Measure Evaluation and Development 
The AGA recently published three guidance documents to assist in interpreting the 
available evidence regarding COVID-19, with the goals of summarizing data and 
providing evidence-based recommendations for 1) evaluation and management of Gl 
and liver manifestations of COVID-19; 2) risk of COVID-19 transmission during 
endoscopy with recommendations for personal protective equipment (PPE); and 3) the 
role of implementing a SARS-CoV2 pretesting strategy prior to endoscopy5-7.  
The aggregate recommendation statements from these documents, exclusive of good 
practice statements, were evaluated for development as potential quality measures. 
Best practice statements which had their certainty assessed using a GRADE (Grading 
of Recommendations Assessment, Development and Evaluation) framework were also 
evaluated as they pertained to recommendations for the consultative management of 
patients with COVID-19.  




A standardized process first implemented by the AGA in 2016 and outlined elsewhere8 
was utilized and concordant with previously employed methods for measure 
development9. Optimal understanding of this measure evaluation process will be 
enhanced by reading applicable portions of the topic guidelines. Briefly, the AGA Quality 
Committee follows a “guidelines to measures” protocol that is based on best practices 
outlined by the American Thoracic Society10. This process relies on the evaluation of 
forthcoming guideline recommendations to be reviewed by the QC. Recommendation 
statements are evaluated as potential measure concepts along several axes, including 
the strength of the recommendation and quality of the evidence as specified using 
GRADE methodology. Only those statements with strong recommendations based on 
high or moderate quality evidence are considered for further measure development, 
which includes an assessment of their potential utility for practicing gastroenterologists. 
This assessment involves QC subcommittee analysis of measure importance and, when 
appropriate, is followed by the formal creation of a measure prioritization brief outlining 
the decision rationale whereby topics are rated on their meaningfulness, potential 
magnitude of effect, quality gaps, feasibility, and applicability to gastroenterologists. 
High priority measure concepts subsequently undergo review and voting by the entire 
QC ahead of a 30-day public comment period prior to testing and formal adoption. 
Finally, measures that receive 60 percent or more of the full QC vote will be 
recommended for national implementation. 
 
Recommendations 
Maintaining high-quality care is essential in a pandemic, not only to facilitate early 
diagnosis and detection, but also to halt its spread and optimize the use of limited 
resources. Developing measures to define high-quality care for use throughout the 
COVID-19 pandemic is challenging. Best practice recommendations are derived from a 
synthesis of the currently available data which, despite the abundance of interest in the 
topic, remains limited to-date. The dynamically changing prevalence rates and resource 
availability assessments continue to change and therefore the evidence regarding 
diagnosis and treatment is evolving, too. While working toward establishing a 
measurable standard for high-quality care for COVID-19, rapid dissemination of quality 
and peer-reviewed data such as that found in the recent guidance documents is 
paramount. 
Within this context, the QC does not currently recommend the development of any 
quality measure concepts for pre-procedure testing, completing endoscopic procedures, 
or for the consultative management of COVID-19 patients. Each recommendation 
statement was independently evaluated and an assessment was made as outlined in 
Table 1. The most frequently identified limitation for further quality measure concept 
development is related to insufficient quality of available evidence and, relatedly, the 
strength of recommendations. For example, in the instance of performing lower GI 
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procedures the use of N95 (or N99 or PAPR) masks is given a strong recommendation 
with low quality evidence. In other important instances, consequential data are lacking. 
In the instance of abnormal liver associated enzymes, there are not enough data that 
evaluating for alternative etiologies is a change from the current practice paradigm. 
Similarly, the recommendations to avoid pre-procedure testing in high prevalence areas 
may be in conflict with local or state-level recommendations with associated impacts on 
patient care.  
Another commonly identified factor limiting measure development is the lack of 
described quality gaps. Although these areas have not been broadly researched at this 
time, in the instance of performing any GI procedure in known or presumptively COVID-
19 positive patients, it is unlikely anyone would be using surgical masks only as part of 
their PPE. Furthermore, reliable and specified means through which adherence can be 
calculated is critical for quality measures. As a result, although using two pairs of gloves 
as part of PPE is undoubtedly relevant, reliably evaluating and calculating measure 
satisfaction in this area would be challenging. 
Among other features particularly relevant to quality measure development is some 
performance stability over time, to both establish a benchmark and later against which 
comparisons can be made to measure practice. Necessarily, both the ongoing nature 
and expected impermanence of the current pandemic conditions likely limit the impact 
that quality measures would have as such a process is routinely expected to require 
several cycles of specification, testing, validation, and final approval for inclusion in 
quality payment programs. 
 
Discussion and Future Directions 
Given the novelty of COVID-19 and its profound effects on individual and public health, 
this year has seen the generation and publication of enormous volumes of data to guide 
clinical practice. The AGA’s CGC has created a comprehensive and systematic 
evaluation of the available data to provide much needed guidance regarding pre-
procedure testing and peri-procedure safety as well as a context for interpreting 
gastrointestinal signs and symptoms related to this viral illness. Although rigorously 
evaluated, these guidance recommendations come with several important caveats, 
which is primarily related to quality of available evidence and its expected evolution. 
Together with their time-limited nature, these recommendations do not currently satisfy 
criteria for further development into quality measures. 
A critical initial step in evaluating guidance statements for measure concept 
development is assessing the quality of evidence and strength of recommendation. In 
the case of the COVID-related statements, few of the current statements achieved 
sufficient moderate to high quality evidence and sufficiently strong recommendations. 
Furthermore, the utility of any quality measure is dependent on the existence of gaps in 
care delivery. There are no data available to suggest any such gaps exist with respect 
to patient care. Finally, all practice patterns are dependent on local disease prevalence 
and acknowledged as such in the guidelines. The nature of the evolving pandemic 
necessarily implies dynamic responses and adaptations will be employed within that 
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context. Together these realities limit the impact any such potential quality measure 
would have on practice. 
However, the QC strongly believes that the best practices outlined in the CGC 
guidelines should be followed whenever possible and appropriate. Importantly, the lack 
of specified quality measures does not indicate a lack of importance to quality 
improvement as it pertains to COVID care. The duration in which we will be practicing in 
the current state is unknown and therefore identifying opportunities for improvement is 
critical. Because of the increasing evidence base, establishing metrics for COVID-19 
care is a first step. This will require more data and demonstrable gaps in the quality of 
care.  
There is also now robust evidence for disparities in outcomes between patient groups. It 
is highly likely care delivery gaps are also present, both among socioeconomically 
disadvantaged patient populations and across health systems; these are probably 
further pronounced during periods of healthcare strain such as occurs when 
communities experience outbreaks and “surges.” Monitoring for variations in care 
delivery and outcomes in these situations will be important and are sources of particular 
interest for improvement. 
In contrast, generating a quality measure, including those on which clinicians can report 
as part of a systematic quality program such as the Merit-based Incentive Payment 
System (MIPS), relies on an extensive process of specification, testing, and formal 
programmatic submission11. This is therefore a more distal goal. There are already 
examples of projects that aimed to assess adherence and outcomes related to such 
pre-procedure testing12. More data in this regard will be increasingly valuable the longer 
the pandemic lasts. 
In conclusion, the current best practices, guidelines and recommendation statements 
from the AGA represent an essential synthesis of the available data regarding COVID-
19 regarding pre-procedure testing and peri-procedure safety as well as context for 
interpreting gastrointestinal signs and symptoms related to this viral illness. The quality 
of the evidence, strength of recommendations, and lack of known quality gaps currently 
preclude the development of quality measures at this time. These, and other concepts, 
are expected to evolve with the pandemic and growing evidence base. The QC 
encourages practitioners to adhere to these recommendations when appropriate and 
feasible and track their impact through active engagement in quality improvement. With 
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Table 1.   Summary of recommendations and rationale for quality measure development
 
Statement GRADE Decision Rationale 
AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic 
In health care workers performing 
upper GI procedures, regardless of 
COVID-19 status, the AGA 
recommends use of N95 (or N99, or 
PAPR) masks instead of surgical 











Lack of demonstrated or 
suspected quality gap, 
measurement challenges, and 
uncertain magnitude of effect. 
 
Variation for N95 use in this 
context exists; as pre-procedure 
testing is more widely available, 
an important caveat for 
contextualizing this 
recommendation, there may be 
limited impact of this 
recommendation. 
 
In health care workers performing 
lower GI procedures, regardless of 
COVID-19 status*, the AGA 
recommends the use of N95 (or N99 
or PAPR) masks instead of surgical 
masks as part of appropriate PPE. 
Strong 
recommendation, 








Insufficient certainty of evidence 
and measurement challenges. 
 
Variation for N95 use in this 
context exists; practically, 
physicians performing a 
combination of upper and lower 
endoscopy likely would refrain 
from donning and doffing 
throughout the day. Also, local 
medical boards (e.g., Texas) 
have stronger PPE requirements. 
In health care workers performing 
upper GI procedures, in known or 
presumptive COVID-19 patients, the 
AGA recommends against the use of 
surgical masks only, as part of 
adequate PPE.  
Strong 
recommendation, 








Insufficient certainty of evidence 
and lack of demonstrated or 
suspected quality gap. 
 
In extreme resource-constrained 
settings involving health care workers 
performing any GI procedures, 
regardless of COVID-19 status, the 
AGA suggests extended use/re-use 
of N95 masks over surgical masks, 
as part of appropriate personal 
protective equipment.  
Conditional 
recommendation, 








Insufficient quality of evidence 
and strength of recommendation. 
 
In health care workers performing Strong No Lack of demonstrated or 
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any GI procedure, regardless of 
COVID-19 status, the AGA 
recommends the use of double 
gloves compared with single gloves 









suspected quality gap and 
measurement challenges. 
 
In health care workers performing 
any GI procedure, with known or 
presumptive COVID-19, the AGA 
suggests the use of negative 
pressure rooms over regular 
endoscopy rooms, when available. 
Conditional 
recommendation, 








Insufficient strength of 




AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARSCoV2 Testing 
and Endoscopy¶ 
For most endoscopy centers, the 
AGA suggests implementing a pre-
testing strategy using information 
about prevalence and test 
performance (sensitivity/specificity) in 
combination with considerations 
about the benefits and downsides of 
the strategy. The prevalence of  
asymptomatic SARS-CoV2 infection 
for most endoscopy centers will 











Insufficient strength of 
recommendation and certainty of 
evidence.  
 
Practical limitations include 
estimating local prevalence 
especially during “surges,” 
accounting for patient mobility 
with contact tracing and 
assessing test characteristics. 
 
For endoscopy centers where the 
prevalence of asymptomatic SARS-
CoV2 infection is low (<0.5%), the 
AGA suggests against implementing 











Insufficient strength of 
recommendation and certainty of 
evidence.  
 
Practical limitations include 
estimating local prevalence 
especially during “surges,” 
accounting for patient mobility 
with contact tracing and 
assessing test characteristics. 
For a small number of endoscopy 
centers in high prevalence areas, the 
AGA suggests against implementing 
a pre-testing strategy. In “hotspots,” 
endoscopy should only be reserved 
for emergency or time-sensitive 
procedures with use of N95/N99 












Insufficient strength of 
recommendation and certainty of 
evidence.  
 
Practical limitations include 
estimating local prevalence and 
defining a “hotspot,” accounting 
for patient mobility with contact 
tracing and assessing test 
characteristics. Implementation 
challenges include some areas 
where testing is universal to 
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facilitate re-triage COVID-positive 
patients as the definition for time-
sensitive procedures may vary.  
For all endoscopy centers, the AGA 
recommends against serologic 
testing as part of a pre-testing 












Insufficient certainty of evidence.  
 
Additional data are needed to 
assess potential benefits and 
harms to such an approach. 
AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis 
of International Data, and Recommendations for the Consultative Management of Patients with COVID-
19 
In outpatients with new onset of 
diarrhea, (i) ascertain information 
about high risk contact exposure (ii) 
obtain a detailed history of symptoms 
associated with COVID-19, including 
fever, cough, shortness of breath, 
chills, muscle pain, headache, sore 
throat, or new loss of taste or smell 
(iii) obtain a thorough history for other 
GI symptoms, including nausea, 









No demonstrated or suspected 
quality gap and uncertain 
magnitude of effect. 
 
Obtaining a detailed history of GI 
symptoms and non-GI symptoms 
is essential to evaluating all 
patients during the pandemic and 
expected as part of routine 
gastrointestinal care which may 
limit impact of this 
recommendation. 
 
In outpatients with new onset GI 
symptoms (e.g., nausea, vomiting, 
abdominal pain, diarrhea) monitor for 
symptoms associated with COVID-19 
as GI symptoms may precede 
COVID-related symptoms by a few 
days. In a high COVID-19 prevalence 










No demonstrated or suspected 
quality gap and uncertain 
magnitude of effect. 
 
The reported prevalence continue 
to vary, with different thresholds 
for high rates, indicating a broad 
presentation, and often lack 
thereof, of GI symptoms. 
In hospitalized patients with 
suspected or known COVID-19, 
obtain a thorough history of GI 
symptoms (nausea, vomiting, 
abdominal pain, diarrhea) including 










No demonstrated or suspected 
quality gap and uncertain 
magnitude of effect. 
 
The majority of studies evaluated 
of GI symptoms in COVID-19 
focused on hospitalized patients, 
in whom a direct association with 
COVID-19, cannot be confirmed. 
Further studies are warranted to 
determine the characteristics, 
including onset and duration, of 
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GI symptoms in relation to other 
COVID-19 symptoms, in 
hospitalized and outpatient 
settings, in order to develop 
measures based on high quality 
evidence. 
There is presently inadequate 
evidence to support stool testing for 
diagnosis or monitoring of COVID-19 








Insufficient quality of evidence 
In patients (outpatients or inpatients) 
with elevated LFTs in the context of 
suspected or known COVID-19, 








No demonstrated or suspected 
quality gap and uncertain 
magnitude of effect. 
Referenced studies did not report 
whether alternative etiologies of 
elevated LFTs were considered 
and doing so is expected as part 
of routine gastrointestinal care 
which may limit  impact of this 
recommendation. 
In hospitalized patients with 
suspected or known COVID-19, 
obtain baseline LFTs at the time of 
admission, and consider LFT 
monitoring throughout the 
hospitalization, particularly in the 









No demonstrated or suspected 
quality gap and uncertain 
magnitude of effect. 
In hospitalized patients undergoing 
drug treatment for COVID-19, 
evaluate for treatment-related GI and 








No demonstrated or suspected 
quality gap. 
Personal protective equipment: PPE 
*These recommendations assume the absence of widespread reliable rapid testing for the diagnosis of
COVID-19 infection or immunity
¶These recommendations assume that all patients are systematically screened for COVID-19 symptoms
using the CDC screening checklist and are required to wear masks while in the endoscopy unit.
